[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Third Military Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":396},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,63,84,113,140,164,190,211,237,270,298,324,345,370],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634191","high-flow-nasal-cannula-oxygen-therapy-versus-conventional-oxygen-therapy-in-high-altitude-pulmonary-edema-100634191",false,"NCT07536477","High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema","High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in Patients With High-altitude Pulmonary Edema: A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Onset of symptoms related to HAPE (including dyspnea at rest, cough, or exercise intolerance) within 7 days of ascending to high altitude (≥2500m);\n3. Diagnosis of HAPE according to the STAR data reporting guidelines, requiring at least two symptoms (dyspnea at rest, cough, weakness\u002Fdecreased exercise performance, or chest tightness\u002Fcongestion) and two clinical signs (rales or wheezing in at least one lung field, central cyanosis, tachypnea, or tachycardia);\n4. Radiographic evidence of pulmonary edema on chest X-ray or CT;\n5. Refusal or inability to undergo immediate descent at the time of presentation;\n6. Capability and willingness to provide written informed consent.\n\nExclusion criteria:\n\n1. Known or clinically confirmed pregnancy;\n2. Requirement for emergency intubation (as assessed by the treating clinician) due to cardiac\u002Frespiratory arrest, hemodynamic instability, airway compromise, severe hypoxia, or impaired consciousness, etc;\n3. Pulmonary edema or hypoxemia resulting from other medical conditions (e.g., cardiogenic pulmonary edema, sepsis, chronic obstructive pulmonary disease (COPD), pneumothorax, massive pleural effusion, chest trauma, etc.);\n4. Glasgow Coma Scale (GCS) score ≤ 12;\n5. PaCO₂ \\> 55 mmHg;\n6. Presence of high-altitude cerebral edema;\n7. Receipt of any respiratory support therapy (other than conventional oxygen therapy) prior to admission;\n8. Presence of any contraindication to conventional or nasal oxygen therapy;\n9. Presence of severe medical conditions or abnormal clinical laboratory findings that, in the investigator's judgment, may pose a risk to the patient's safety or interfere with the study's execution and participant completion;\n10. Current participation in other clinical trials;\n11. Refusal to sign the informed consent form.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate whether High-flow Nasal Cannula Oxygen Therapy (HFNC) provides superior respiratory support compared to Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE).",[26],"High-altitude Pulmonary Edema",[28],"HAPE","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":33},"2026-04-25",{"date":37,"type":20},"2029-04-22",{"name":39,"class":40},"Third Military Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100405332","erythrocytapheresis-for-chronic-mountain-sickness-100405332","NCT04557995","Erythrocytapheresis for Chronic Mountain Sickness","Efficacy and Safety of Erythrocytapheresis in Chronic Mountain Sickness: the ESCAPE-CMS Trial","Inclusion:\n\n1. Age ≥18 years;\n2. High-altitude residents or long-term dwellers (continuous residence at ≥2500 meters above sea level for at least 1 year), with no travel history to low-altitude areas in the past 3 months;\n3. Hemoglobin (Hb): Men: ≥210 g\u002FL, Women: ≥190 g\u002FL; at least one symptom or sign: headache, dizziness, dyspnea, palpitations, sleep disturbances, fatigue, localized cyanosis, burning sensation in palms\u002Fsoles, venous dilatation, muscle\u002Fjoint pain, loss of appetite, poor concentration, or memory changes; CMS total score ≥6;\n4. Written informed consent obtained from patients or their legal representatives.\n\nExclusion:\n\n1. Hematocrit \\\u003C 60%;\n2. Patients with erythrocytosis attributable to: polycythemia vera; secondary erythrocytosis due to dehydration, cyanotic congenital heart disease, or chronic obstructive pulmonary disease; or other underlying hematologic or oncologic conditions;\n3. Patients with active pneumonia, pulmonary embolism, or severe organ dysfunction (including cardiac, hepatic, or renal failure);\n4. Patients with contraindications to study procedures (including erythrocytapheresis, pulmonary function tests, or incremental shuttle walk test), such as impaired consciousness, pneumothorax, severe arrhythmia, or significant coagulation disorders;\n5. Patients who have received CMS-specific interventions within the last 6 months, including phlebotomy, erythrocytapheresis, or targeted pharmacotherapy;\n6. Patients currently pregnant, breastfeeding, or planning to become pregnant within 1 year;\n7. Any terminal condition with an estimated life expectancy of \\\u003C 6 months;\n8. Current participation in other clinical trials.",{"count":50,"type":20},112,[23],"The study aims to explore the efficacy and safety of erythrocytapheresis in chronic mountain sickness",[54],"Chronic Mountain Sickness","2026-03-29",{"date":57,"type":33},"2026-04-02",{"date":59,"type":33},"2025-07-21",{"date":61,"type":20},"2029-10-01",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":41},"100630502","diagnostic-value-and-safety-of-combined-biopsy-for-mediastinal-metastasis-of-lung-cancer-100630502","NCT07488507","Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer","Diagnostic Value and Safety of EBUS-TBNA Combined With Medaistinal Cryobiopsy for Mediastinal Metastasis of Lung Cancer","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Presence of at least one mediastinal lesion (short-axis diameter ≥10 mm) confirmed by thin-slice chest CT;\n3. Patients who have not undergone prior mediastinal biopsy and require further mediastinal biopsy to confirm etiology or pathological subtype, meeting at least one of the following criterias:\n\n(1) suspected lung cancer diagnosed by two senior physicians; (2) confirmed lung cancer (requiring mediastinal staging); (3) recurrent lung cancer; 4.Patients must have completed all required preoperative laboratory tests and necessary examinations (e.g., cardiac ultrasound, CTA) to rule out contraindications; 5. Patients are informed and capable of providing written informed consent.\n\nExclusion Criteria:\n\n1. Presence of severe cardiopulmonary disease, coagulation disorders, massive hemoptysis, poor tolerance to anesthesia, or other contraindications related to bronchoscopy;\n2. Intraoperative endobronchial ultrasound exploration of the lesion failed to detect the target lesion despite \\> 20 minutes of attempts;\n3. Lesions identified as abscesses or cysts;\n4. Presence of mental illness, severe neurosis, or other conditions that preclude the provision of informed consent;\n5. Patients who have participated in other clinical trials within 3 months;\n6. Any other conditions considered to be inappropriate to be involved in this trial.",{"count":71,"type":20},240,[23],"The study is aimed o evaluate the diagnostic performance and treatment guidance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) combined with transbronchial mediastinal cryobiopsy (EBUS-TBMCB) in patients with mediastinal metastases of lung cancer.",[75],"Mediastinal Metastases of Lung Cancer","2026-03-18",{"date":78,"type":33},"2026-03-23",{"date":80,"type":20},"2026-03-20",{"date":82,"type":20},"2030-03-01",{"name":39,"class":40},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":5},"100614308","phase-3-efficacy-and-safety-of-lubiprostone-in-the-treatment-of-slow-transit-constipation-100614308","NCT07277907","Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation","Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled Trial","STOPS 03","Inclusion Criteria:\n\n1. Patients voluntarily participated in the study and provided signed informed consent;\n2. Met the Rome IV diagnostic criteria for functional constipation;\n3. Had fewer than 3 spontaneous bowel movements (SBMs) per week;\n4. More than 20% the radio-paque markers localized in the colon after 72 hours based on colonic transit studies;\n5. Were able to complete the bowel movement diary and study questionnaires as required by the study protocol;\n6. Agreed to use effective contraception from the time of signing the informed consent form until 3 months after the last dose of the study drug;\n7. Aged 18 years or older, both males and females.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients with severe outlet obstruction constipation (e.g. Oxford Grade IV or above for rectal prolapse, rectocele \\> 3.1 cm, puborectalis syndrome).\n3. Patients with hyperthyroidism or hypothyroidism.\n4. Patients with opioid-induced constipation.\n5. Patients with megacolon or megarectum.\n6. Patients with apparent mechanical intestinal obstruction.\n7. Patients with inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis).\n8. Patients with malignant tumors of the digestive system.\n9. Patients with a history of colorectal surgery.\n10. Patients with a previous history of taking lubiprostone.\n11. Patients with severe symptoms of depression or anxiety.\n12. Patients with known or suspected hypersensitivity to lubiprostone\u002Fpolyethylene glycol 4000 or any excipients.\n13. Patients requiring medications for Parkinson's disease, antipsychotics, antimanic agents, or psychostimulants.\n14. Patients with severe cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurological, or psychiatric diseases.\n15. Other patients deemed by the investigator as unsuitable for participation in this trial.",{"count":93,"type":20},346,[95],"PHASE3","Lubiprostone has established efficacy and a favorable safety profile in chronic constipation and irritable bowel syndrome with constipation (IBS-C). However, clinical data specifically supporting its use in slow-transit constipation (STC), a distinct subtype of chronic constipation, remains limited.",[98,99],"Slow Transit Constipation","Pharmacotherapy",[98,101,102,103,104],"Lubiprostone","Polyethylene Glycol","Randomized Controlled Trial","medication","2026-01-16",{"date":107,"type":33},"2026-01-20",{"date":109,"type":33},"2025-11-13",{"date":111,"type":20},"2027-11-30",{"name":39,"class":40},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":41},"100605071","effects-of-compound-ejiao-syrup-on-exercise-tolerance-and-quality-of-life-in-critically-ill-patients-after-icu-discharge-a-double-blind-multicenterrandomized-controlled-clinical-study-100605071","NCT07157748","Effects of Compound Ejiao Syrup on Exercise Tolerance and Quality of Life in Critically Ill Patients After ICU Discharge: A Double-Blind, Multicenter,Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* 1\\. Obtain informed consent; 2. Age between 18 and 75 years (inclusive); 3. Discharged from the ICU within 24 hours; 4. Received mechanical ventilation for at least 48 hours during this ICU stay; 5. Has been in the ICU for at least 8 days but no more than 28 days; 6. Enteral nutrition has been initiated. 7. Able to breathe spontaneously, with an oxygenation index (PaO2\u002FFiO2) ≥ 200, and not requiring continuous high-flow oxygen therapy (e.g., nasal cannula flow ≤ 5 L\u002Fmin); 8. Glasgow Coma Scale (GCS) score ≥ 13 at ICU discharge, and able to cooperate with study-related tests and follow-up; 9. Able to perform simple bedside activities with assistance (e.g., sitting up, standing, or short-distance walking); 10. No severe heart failure, no end-stage chronic respiratory failure, no lower-limb conditions that impair mobility, and no severe central nervous system disease; Able to stand independently and expected to complete the 6MWT at follow-up.\n\nExclusion Criteria:\n\n* 1\\. Patients expected to die or for whom life-sustaining treatment will be withdrawn within 48 hours after ICU discharge; 2. Patients who need to be readmitted to the ICU within 1 week after ICU discharge; 3. Patients with persistent severe hepatic failure at ICU discharge (Child-Pugh class C); 4. Patients with persistent chronic kidney disease at ICU discharge (creatinine clearance \\\u003C 40 mL\u002Fmin); 5. Pregnant or breastfeeding patients; 6. Patients unable to walk independently before ICU admission (those who can walk independently with assistive devices may be included); 7. Traumatic brain injury, primary cerebrovascular diseases, brain tumors, or intracranial infections; 8. Primary cognitive impairment: Alzheimer's disease, vascular dementia, hydrocephalus, etc., and other serious central nervous system diseases; 9. History of psychiatric disorders such as depression, anxiety, or schizophrenia; 10. Occurrence of respiratory or cardiac arrest; 11. Patients with known cognitive impairment, lower-limb injury, systemic neuromuscular disease, or cranial\u002Fspinal conditions that could affect outcome assessment; 12. Patients currently taking other Qi- and blood-tonifying traditional Chinese medicines or patent Chinese medicines.","75 Years",{"count":121,"type":20},178,[23],"This study, titled \"Effect of Compound Ejiao Jiang on Exercise Tolerance and Quality of Life of Critically Ill Patients after Discharge from ICU: A Double-Blind, Multicenter, Randomized Controlled Clinical Study (LIFT Study),\" intends to enroll 156 patients (78 in the experimental group and 78 in the control group). A double-blind design will be adopted, with patients receiving Compound Ejiao Jiang (20 ml each time, three times a day for 90 consecutive days) or a placebo for intervention. The primary outcome measure is the 6-minute walking distance on the 90th day after randomization. Meanwhile, secondary endpoints such as physical function, quality of life, and nutritional and inflammatory indicators will also be monitored. The aim of this study is to explore the rehabilitation value of Compound Ejiao Jiang for patients with post-intensive care syndrome (PICS) through high-level evidence-based medicine methods and to provide scientific evidence for the integrated traditional Chinese and Western medicine approach to improving the long-term prognosis of critically ill patients",[125],"Critically Ill Patients",[127,128,129,130],"critically ill patients","exercise tolerance","exercise quality","Compound Ejiao Oral Liquid","NOT_YET_RECRUITING","2025-08-28",{"date":134,"type":33},"2025-09-05",{"date":136,"type":20},"2025-12",{"date":138,"type":20},"2027-09",{"name":39,"class":40},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":150,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":41},"100603503","efficacy-of-spironolactone-combined-with-antihypertensive-drugs-in-patients-with-primary-aldosteronism-100603503","NCT07137364","Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism","Inclusion Criteria:\n\n1. Male or female, aged 30\\~65 years.\n2. PA patients with positive screening tests and saline suppression tests, and with AVS to determine lateralization. These patients have hypertension defined as office blood pressure ≥ 140\u002F90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130\u002F80 mmHg, daytime blood pressure ≥ 135\u002F85 mmHg, or nighttime blood pressure ≥ 120\u002F70 mmHg.\n3. Patients with unilateral aldosterone-producing adenoma who decline surgery, or patients with non-adenoma, unilateral PA confirmed by AVS and meeting the above PA-related hypertension criteria.\n4. Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hyperkalemia.\n2. Renal impairment or have history of renal disease: serum creatinine \\> 1.5 × upper limit of normal (ULN), dialysis, or nephrotic syndrome.\n3. Other confirmed secondary hypertension: pheochromocytoma, Cushing's syndrome, thyroid disorders, parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence, etc.\n4. Adrenal insufficiency.\n5. Heart failure with NYHA class II-IV or stroke.\n6. Acute infection, malignancy, severe arrhythmia, psychiatric disorders, or drug\u002Falcohol abuse.\n7. Significant hepatic dysfunction or have history of liver disease: AST or ALT \\> 2 × ULN, cirrhosis, hepatic encephalopathy, esophageal varices or portosystemic shunt.\n8. Pregnancy or lactation.\n9. Participation in another clinical trial within the past 3 months.\n10. Inability to complete follow-up.\n11. Refusal to provide informed consent.","30 Years","65 Years",{"count":149,"type":20},350,"12 Months","OBSERVATIONAL","The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:\n\n1. What is the long-term effect of spironolactone treatment for lateralized PA?\n2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.",[154,155],"Primary Aldosteronism","Hypertension","2025-08-15",{"date":158,"type":33},"2025-08-22",{"date":160,"type":33},"2022-05-01",{"date":162,"type":20},"2026-04-30",{"name":39,"class":40},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":41},"100596916","transcutaneous-auricular-vagus-nerve-stimulation-as-adjuvant-treatment-for-sepsis-patients-100596916","NCT07051694","Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients","Exploratory Study on Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients","TaVNS-Sepsis","Inclusion Criteria:\n\n* Age 18-80\n* Sepsis was diagnosed per the Sepsis-3 criteria (SCCM\u002FESICM 2016) as infection with SOFA score ≥ 2\n* ICU admission within 7 days after sepsis onset\n* Informed consent was obtained from patients\u002Fguardians\n\nExclusion Criteria:\n\n* severe ARDS defined by PaO₂\u002FFiO₂ ≤100 mmHg with PEEP ≥5 cm H₂O\n* HR\\>120 per minute\n* epinephrine or norepinephrine \\>1ug\u002Fkg\u002Fmin\n* severe underlying pulmonary diseases including interstitial lung disease, -\n* diffuse alveolar hemorrhage, severe asthma, or lung cancer\n* taVNS contraindications: existing pacemakers, cochlear implants, or other active implantable electronic medical devices\n* dermatologic or infectious disorders affecting the auricular region\n* pregnancy or lactation\n* participation in other clinical trials\n* inability to remain motionless during treatment (e.g., due to epilepsy or Parkinson's disease)","80 Years",{"count":174,"type":20},60,[23],"The goals of this randomized clinical trial are to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standard intensive care on systemic organ function in septic patients, and exploring its potential mechanisms for improving overall outcomes in sepsis.The main question it aims to answer is whether taVNS can reduce the severity of sepsis patients by ameliorating systemic inflammation.Participants will receive standard intensive care treatment and be randomized to receive the taVNS or sham taVNS as adjuvant treatment twice a day for 7 consecutive days. Several evaluations will be done before and after the intervention.",[178],"Sepsis",[180,181],"sepsis","transcutaneous auricular vagus nerve stimulation","2025-06-30",{"date":184,"type":33},"2025-07-04",{"date":186,"type":33},"2025-02-27",{"date":188,"type":20},"2026-12-31",{"name":39,"class":40},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":41},"100595756","parlar-02-trialmodified-transanal-drainage-tube-use-for-preventing-anastomotic-leakage-100595756","NCT07036588","PARLAR-02 Trial：Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage","Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage After Low Anterior Resection in Patients With Rectal Cancer: A Randomized Clinical Trial(PALARC 02)","Inclusion Criteria:\n\n* Rectal adenocarcinoma (confirmed by pathology);\n* Tumor location: The lower edge is ≤10 cm from the anal verge;\n* Age: ≥18 and ≤80 years old;\n* ASA ≤3 ;\n* After assessment, laparoscopic\u002Frobotic sphincter - preserving surgery for rectal cancer is feasible;\n* T2 - 4N0 - 3M0\\~T0 - 1N1 - 3M0 \\& non- local recurrence;\n* Signed informed consent form;\n* Able to understand the risks of participating in the trial.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Presence of multiple primary colorectal cancers;\n* History of long - term use of immunosuppressants or corticosteroids;\n* Patients with severe mental illness or uncontrolled infection before surgery;\n* Pregnant or breastfeeding women;\n* Bowel obstruction before surgery.",{"count":198,"type":20},968,[23],"Surgical resection remains the primary treatment for rectal cancer, but the postoperative incidence of anastomotic leakage (AL) is relatively high. AL not only increases the medical burden on patients, prolongs hospital stays, raises the need for secondary surgery, and elevates perioperative mortality, but also increases the long-term risk of local recurrence and reduces survival rates. There is an urgent need for a simple, effective treatment method that minimizes the burden on patients to prevent anastomotic leakage.\n\nThe preoperative placement of a transanal drainage tube (TDT) is believed to effectively drain gas and feces from the intestinal lumen, thereby reducing intestinal pressure and alleviating tension at the anastomotic site, thus preventing AL. Previous studies have shown that traditional drainage tubes cannot effectively prevent leakage. Given the limitations of existing research on traditional TDTs, we plan to use a modified TDT (which allows postoperative irrigation and utilizes a balloon to block feces from adversely affecting the anastomosis) to conduct a randomized, parallel-controlled trial. This study aims to further investigate the role of the modified TDT in preventing and treating anastomotic leakage following rectal surgery",[202],"Anastomotic Leak","2025-06-16",{"date":205,"type":33},"2025-06-25",{"date":207,"type":20},"2025-07-01",{"date":209,"type":20},"2030-12-31",{"name":39,"class":40},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":219,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":41},"100567978","comparison-of-electrolyte-beverages-and-water-as-solvents-for-bowel-preparation-100567978","NCT06675227","Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation","Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation: A Single-Blind, Prospective, Multicenter Randomized Controlled Trial","EBSBP-01","Inclusion Criteria:\n\n1. Healthy individuals or those with mild or well-controlled chronic diseases.\n2. Patients scheduled for outpatient colonoscopy.\n3. Patients prescribed sodium phosphate or polyethylene glycol for bowel preparation.\n4. Willing to participate and sign the informed consent form.\n5. Age ≥18 years\n6. ECOG performance status \\\u003C2\n\nExclusion Criteria:\n\n1. Patients who refuse to participate in the study.\n2. Patients requiring enema preparation.\n3. Uncontrolled hypertension.\n4. Patients with diabetes.\n5. Pregnant patients.\n6. Suspected bowel obstruction.\n7. Risk of aspiration.\n8. Patients with severe ulcerative colitis, gastric retention, bowel perforation, toxic colitis, or megacolon.\n9. Patients with severe systemic diseases (including NYHA class 3-4 heart failure, Child-Pugh class C liver failure).\n10. Patients with a known allergy to polyethylene glycol.\n11. Patients with a history of major gastrointestinal surgery or any other conditions that may interfere with study outcomes or adherence.",true,{"count":221,"type":20},2766,[23],"Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.\n\nThe aim of this study is to test whether Electrolyte Beverages as solvents can improve the cleanness of bowel preparation and the satisfaction of patients.",[225],"Bowel Preparation Before Colonoscopy",[227,228],"bowel preparation","Electrolyte Beverages","2025-03-17",{"date":231,"type":33},"2025-03-20",{"date":233,"type":33},"2024-11-11",{"date":235,"type":20},"2025-12-31",{"name":39,"class":40},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":245,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},"100577332","epidural-spinal-cord-stimulation-for-lower-limb-impairment-in-adrenomyeloneuropathy-100577332","NCT06796920","Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy","Spinal Cord Stimulation Surgery for Improving Lower Limb Motor Dysfunction in Adrenomyeloneuropathy (AMN): A Prospective, Multicenter, Single-Arm, Self-Controlled Study.","EPIC-AMN","Inclusion Criteria:\n\n* Conforming to the diagnostic criteria of AMN, with a definite genetic testing report, and complicated by lower limb motor function disorders;\n* Capable of normal communication and able to complete scale tests independently (as determined by on-site scale tests);\n* Willing to participate in this study after giving informed consent;\n* The muscle tone of the patient's bilateral lower extremities was elevated.\n\nExclusion Criteria:\n\n* Other inherited diseases;\n* Other severe central nervous system diseases;\n* History of brain surgery;\n* Psychiatric and psychological diseases such as depression and anxiety;\n* The presence of metallic foreign bodies or prostheses (such as cardiac pacemakers, insulin pumps) in the body, claustrophobia, and other contraindications for MRI;\n* Informed consent was not obtained;\n* Unable to tolerate MRI-related examinations;\n* Received anticoagulant, antispasmodic or antiepileptic drug therapies throughout the entire study period;\n* Postoperative wound infection;\n* Other motor disorders, spinal cord pathologies, fractures, osteoarthritis, amputations, scoliosis and other movement-affecting diseases.","MALE","22 Years","50 Years",{"count":249,"type":20},10,[23],"Adrenal spinal neuropathy (AMN) is a rare X-linked genetic disease caused by mutations in the ABCD1 gene, and belongs to a special type of adrenal leukodystrophy. The patient's lower limb strength is weakened, the range of motion of the ankle joint is reduced, the hip flexors are weak and affect walking, and the peripheral nerves and vibration sensation are damaged. As the condition worsens, the lower limb muscle tone changes from hyperactivity to decrease, ultimately transitioning from spastic paralysis to flaccid paralysis. At present, the treatment plan for AMN is not yet perfect, and effective therapies are urgently needed to alleviate symptoms.\n\nSpinal cord electrical stimulation (SCS) is the implantation of a thin electrode into the epidural space of the corresponding spinal segment within the spinal canal. Then connect the electrodes to a nerve stimulator implanted subcutaneously in the iliac region, and use electrical pulses to stimulate the conduction of sensory neurons in the posterior column and posterior horn of the spinal cord for treatment, which can achieve the goal of controlling pain. In addition, SCS has also conducted research on the recovery of lower limb function in paraplegic patients and upper limb function in post-stroke hemiplegic patients, and has improved corresponding motor dysfunction to a certain extent. Spinal cord stimulation may be a potential treatment for motor dysfunction in AMN. Based on the above, this study attempts to evaluate the efficacy of SCS in treating lower limb muscle tone and movement disorders in AMN patients, and explore the potential therapeutic effects and related mechanisms of SCS on AMN.\n\nIn this study, 10 AMN patients will be recruited. After enrollment, preoperative evaluation will be conducted. After preliminary assessment of motor function, neurological evaluation, and other related examinations, lumbar spinal nerve stimulators and pulse generators were implanted in our hospital. After the implantation surgery is completed, depending on the patient's recovery status, they will be transferred to various centers for subsequent rehabilitation treatment within one to two weeks, and then turned on for treatment. Before starting up, a second corresponding inspection and evaluation will be conducted. The third and fourth corresponding inspections and evaluations will be conducted one week and four weeks after startup, respectively. The patient will be discharged 4 weeks after starting up, and then return to the hospital for the fifth and sixth corresponding examinations and evaluations at 4 weeks and 6 months after discharge. Evaluate the effectiveness and safety of SCS in improving lower limb motor dysfunction in AMN patients through statistical analysis.",[253],"Adrenomyeloneuropathy Without Cerebral Involvement",[255,256,257,258,259,260],"Genetic Diseases","Rare Diseases","Spinal Cord Stimulation","Motor Function Recovery","Multicenter Study","Adrenomyeloneuropathy","2025-01-21",{"date":263,"type":33},"2025-01-28",{"date":265,"type":20},"2025-02-10",{"date":267,"type":20},"2027-10",{"name":39,"class":40},4,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":41},"100556312","phase-4-statin-combined-with-amlodipine-treats-primary-aldosteronism-100556312","NCT06523465","Statin Combined with Amlodipine Treats Primary Aldosteronism","A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment","STOP-PA","Inclusion Criteria:\n\n* Clinical diagnosis of primary aldosteronism\n\nExclusion Criteria:\n\n* Allergy to drugs in this study\n* Pregnancy\n* Severe liver and kidney dysfunction\n* Mental illness","70 Years",{"count":280,"type":20},180,[282],"PHASE4","The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.",[154,285,286,155],"Statin","Mineralocorticoid Receptor Antagonist",[288,289,285],"primary aldosteronism","hypertension","2024-11-19",{"date":292,"type":33},"2024-11-22",{"date":294,"type":33},"2024-09-10",{"date":296,"type":20},"2026-09-30",{"name":39,"class":40},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":306,"targetDuration":307,"studyType":151,"phases":4,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":41},"100467154","effect-of-bariatric-surgery-versus-medical-therapy-on-metabolic-syndrome-100467154","NCT05363059","Effect of Bariatric Surgery Versus Medical Therapy on Metabolic Syndrome","Army Medical University","EBSMTMS","1. Inclusion Criteria:\n\n   * BMI\\\u003C35 kg\u002Fm\\^2\n   * Underwent bariatric surgery or medical therapy\n   * Patients met the diagnostic criteria for MS, defined criteria derived from the joint interim statement (JIS)\n2. Exclusion Criteria:\n\n   * Patients who failed to follow up\n   * Insulin dependent diabetes\n   * congenital dementia\n   * brain trauma\n   * epileps\n   * severe hypoglycemic coma\n   * cerebrovascular disease\n   * ischemic\n   * heart disease\n   * renal dysfunction\n   * alcohol abuse\n   * mental illness\n   * psychoactive substance abuse\n   * unwillingness to provide informed consent",{"count":19,"type":20},"5 Years","Bariatric surgery (BS) is known to improve the components of metabolic syndrome (MS) in obese patients. However, few studies have evaluated the impact of bariatric surgery versus medical therapy (MT) in patients with MS, especially in patients with low body mass index (BMI). This study aimed to assess the effect of bariatric surgery on MS in patients with low BMI by comparing BS (BMI\\\u003C35 kg\u002Fm2 and BMI≥35 kg\u002Fm2) with MT (BMI\\\u003C35 kg\u002Fm2). A retrospective study including patients with MS undergoing bariatric surgery and medical therapy at a single institution. We follow up the 5 years effect of bariatric surgery versus medical therapy on the remission of MS, its individual components, atherosclerotic cardiovascular disease (ASCVD) risk, and medication used.",[310],"Metabolic Syndrome",[312,313,314,315],"metabolic syndrome","Medical therapy","Bariatric surgery","body mass index","2024-08-16",{"date":318,"type":33},"2024-08-20",{"date":320,"type":33},"2010-05-01",{"date":322,"type":20},"2024-12-30",{"name":39,"class":40},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":41},"100393929","effects-of-adrenal-artery-ablation-and-spironolactone-in-patients-with-primary-aldosteronism-100393929","NCT04409431","Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism","An Open-label, Cohort Study on Effects and Long-term Prognosis of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism","Inclusion Criteria:\n\n* Primary Aldosteronis diagnosed by increased Renin ratio (ARR) and serum aldosterone levels ≥15 ng \u002F dl, and confirmed by saline injection test or captopril inhibition test.\n* Idiopathic aldosteronism, bilateral adrenal hyperplasia, and unilateral adrenal hyperplasia with no superior secretion confirmed with adrenal CT and adrenal venous blood (AVS).\n* The patients was diagnosed with aldosteronoma or unilateral adrenal hyperplasia but refused to surgical excision.\n* Signed informed consent and agreed to participate in this study.\n\nExclusion Criteria:\n\n* Aldosterone cancer.\n* Hyperkalemia.\n* Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.\n* Secondary hypertension except the primary aldosteronism.\n* Adrenergic insufficiency.\n* Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.\n* Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.\n* Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.\n* Coagulation dysfunction.\n* Pregnant women or lactating women.\n* Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.\n* Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.\n* Allergy or any contraindications for the study drugs, contrast agents and alcohol.\n* Refused to sign informed consent","60 Years",{"count":174,"type":20},[23],"Primary aldosteronism (PA) is one of the most common cause of endocrine and resistant hypertension. Current studies have shown that the activation of the renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in the central or local tissue are the key mechanisms of high blood pressure and its organ damages.\n\nCurrent guidelines suggest that surgery and aldosterone receptor inhibitors are the only treatment for primary aldosteronism. However, only about 35% of aldosterone tumors and a small number of unilateral adrenal hyperplasia can be treated surgically. More than 60% of primary aldosteronism and bilateral adrenal hyperplasia need long-term oral aldosterone receptor inhibitors. At present, spironolactone is the most commonly used aldosterone receptor inhibitor. Long term use of spironolactone may cause hyperkalemia, hyperplasia of male mammary gland, hairiness of female and other adverse reactions. Therefore, the researchers suggest that partial removal of adrenals can reduce aldosterone level, lower blood pressure and restore potassium metabolism balance.\n\nIn patients with primary hyperaldosteronism, the level of aldosterone increases, which can cause vascular endothelial dysfunction, myocardial injury and ventricular fibrosis. The study shows that long-term oral administration of spironolactone can reverse the above cardiovascular damage and correct heart failure. Adrenal artery ablation can reduce aldosterone level, but the long-term effect on cardiovascular system is unknown. In order to confirm the effect of adrenal artery ablation on blood pressure and cardiovascular system, the researchers conducted an open cohort study on patients with primary aldosteronism (including aldosterone, idiopathic aldosteronism and adrenal hyperplasia). To observe the effect of adrenal artery ablation and spironolactone on blood pressure, blood electrolyte, metabolic index, cardiovascular events and cardiovascular death risk in patients with primary aldosteronism, and to explore its efficacy and safety.",[154,155],[154,155,337,338],"Adrenal Artery Ablation","Spironolactone",{"date":318,"type":33},{"date":341,"type":33},"2019-12-01",{"date":343,"type":20},"2025-12-01",{"name":39,"class":40},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":41},"100548325","a-study-on-probiotic-formula-in-autistic-children-100548325","NCT06419530","A Study on Probiotic Formula in Autistic Children","A Double-blind Randomized Clinical Trail Study on the Effectiveness and Safety of Probiotic Formula in Autistic Children With Gastrointestinal Symptoms","Inclusion Criteria:\n\n* Children and adolescents aged 3-11 years old\n* Clinical diagnosis of ASD, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)\n* Associated with gastrointestinal symptoms for at least 14 days (diarrhea, constipation, abdominal pain, bloating and\u002For food allergies\u002Fintolerances)\n* With guardians who can fully understand the informed consent and voluntarily sign the written informed consent\n\nExclusion Criteria:\n\n* Antibiotics or probiotics used within 1 mont\n* Serious gastrointestinal problems that require immediate treatment (such as life-threatening intestinal obstruction, intestinal perforation, intestinal bleeding\n* Medications related to mental disorders or depression\n* Relying on tube feeding\n* Swallowing dysfunction that unable to take capsules\n* History of severe allergies\n* Paticipation in other clinical studies within 4 weeks\n* Poor compliance and have difficulty in completing follow-up.","3 Years","14 Years",{"count":355,"type":20},156,[23],"A Randomized controlled double-blind clinical study on the effectiveness and safety of probiotic formula in Autistic children with gastrointestinal symptoms.",[359],"Autism Spectrum Disorder",[359,361],"Gut microbiota","2024-05-21",{"date":364,"type":33},"2024-05-23",{"date":366,"type":20},"2024-06",{"date":368,"type":20},"2028-06",{"name":39,"class":40},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100512789","phase-2-neoadjuvant-cietai-with-concurrent-chemoradiotherapy-in-local-advanced-rectal-cancer-100512789","NCT05957016","Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer","Neoadjuvant Preoperative Arterial Intervention With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer","Inclusion Criteria:\n\n* Local advanced Rectal cancer: stage T3\u002F4NanyM0 or T1-2N+M0.\n* Ages: 18 to 75.\n* No previously received chemotherapy drugs and radiation therapy.\n* ECOG score: 0 - 2.\n* Appropriate organ function, as defined below:\n\n(Hematology and blood biochemistry examination must be completed within 7 days before the registration date) i) White blood cell count ≥ 4,000\u002Fmm3. ii) Neutrophil count ≥ 1,500\u002Fmm3. iii) Hemoglobin ≥ 10 g\u002FdL. iv) Platelet count ≥ 100,000\u002Fmm3. v) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). vi. Liver function Index (AST \\& ALT) ≤ 1.5 times the upper limit of normal (ULN).\n\nvii. Serum creatinine ≤1.5 times the upper limit of normal or creatinine clearance ≥60 ml\u002Fmin.\n\n* Tolerance of orally administration of capecitabine.\n* Can understand the study, have good compliance, cooperate with follow-up.\n\nExclusion Criteria:\n\n* Severe allergic reaction to humanized antibodies or fusion proteins;\n* Hypersensitivity to any component contained in contrast agent or granule embolic agent;\n* Diagnosed with an immune deficiency or is receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 14 days prior to the first administration of the study, allowing the use of physiological doses of glucocorticoids (≤10mg\u002F day of prednisone or equivalent);\n* Active, known, or suspected autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hypothyroidism, including, but not limited to, these diseases or syndromes). Subjects who have type 1 diabetes, hypothyroidism requiring hormone replacement therapy, skin conditions that do not require systemic treatment (e.g., vitiligo, psoriasis, or hair loss), or conditions that are not expected to recur in the absence of external triggers may be enrolled;\n* Pre-existing severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina pectoris, myocardial infarction, and severe heart valve disease;\n* Active hepatitis B (HBV DNA ≥ 2000IU\u002Fml or 104copies\u002Fml), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of analysis).\n* Active tuberculosis (TB) infection. Patients with a history of active tuberculosis infection within the previous 1 year should be excluded, even if they have been treated; Patients with a history of active tuberculosis infection more than 1 year ago should also be excluded unless the duration and type of antituberculosis therapy previously used is demonstrated to be appropriate.\n* Brain metastases accompanied by symptoms or symptoms controlled for less than 2 months;\n* Received major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to enrollment;\n* Pregnant or lactating female patients (women of childbearing age must confirm that the pregnancy test is negative within 7 days before the first administration of the drug, if it is positive, ultrasound examination must be performed to rule out pregnancy), subjects of childbearing age refuse to accept contraceptive measures; Combined with other malignancies, except cured skin basal cell carcinoma or skin squamous cell carcinoma or in situ carcinoma of any other site\n* Patients with any physical signs or history of bleeding, regardless of severity; Non-healing wounds, ulcers, or fractures were present in patients with any bleeding or bleeding events ≥CTCAE grade 3 during the 4 weeks prior to grouping;\n* Arteriovenous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism;\n* Dementia, altered mental status or any mental illness that would prevent understanding or giving informed consent or completing the questionnaire\n* Other serious concomitant diseases judged by the investigator.",{"count":378,"type":20},90,[380],"PHASE2","To increase the efficacy of neoadjuvant PD-1\u002FPD-1 checkpoint inhibitor in local advanced rectal cancer (LARC), we propose preoperative arterial infusion of Tirellizumab and oxaliplatin followed by tumor artery embolization with concurrent chemoradiotherapy as neoadjuvant regimen for LARC.",[383],"Rectal Cancer",[385,386,387],"local advanced rectal cancer","PD-1 inhibitor","neoadjuvant","2023-08-22",{"date":390,"type":33},"2023-08-23",{"date":392,"type":20},"2023-08-30",{"date":394,"type":20},"2026-06-30",{"name":39,"class":40},""]